GeneSight

MYRIAD TUESDAY DEADLINE: ROSEN, A GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of November 26th Deadline in Securities Class Action | PR Newswire | 11/26/2019

… ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of …

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SEE, MYGN, ZEN and YJ | Globe Newswire | 11/26/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

Follow GeneSight:    

CLASS ACTION UPDATE for CVET, MYGN, ZEN and PLT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders | Globe Newswire | 11/25/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

MYGN FINAL DEADLINE: ROSEN LAW FIRM Reminds Myriad Genetics, Inc. Investors of Tuesday Deadline in Securities Class Action – MYGN | Globe Newswire | 11/25/2019

… ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of …

SHAREHOLDER ALERT: MYGN TEUM ACB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines | The Wapakoneta Daily News | 11/25/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl-and thereby, Foresight-caused …

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MYGN, CC and ET | The Wapakoneta Daily News | 11/25/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl-and thereby, Foresight-caused …

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MYGN, DOMO and PLT | The Wapakoneta Daily News | 11/24/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | PR Newswire | 11/23/2019

… be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. On September 1, 2016 , Myriad announced the completion of its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with two new products—ForeSight and Prelude—in the expanded carrier screening …

4-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | Globe Newswire | 11/23/2019

… 2016 – Aug. 13, 2019 Lead Plaintiff Deadline: Nov. 26, 2019 Contact An Attorney Now: [email protected] (510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint , Defendants misled investors about Myriad Genetics’ GeneSight ®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight ® product, while concealing that GeneSight ® lacked evidence or information sufficient to support tests in its …

3-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | 11/23/2019

510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint, Defendants misled investors about Myriad Genetics’ GeneSight ®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight ® product, while concealing that GeneSight ® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that …

7-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | 11/22/2019

510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint, Defendants misled investors about Myriad Genetics’ GeneSight ®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight ® product, while concealing that GeneSight ® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that …

5-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | 11/22/2019

510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint, Defendants misled investors about Myriad Genetics’ GeneSight ®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight ® product, while concealing that GeneSight ® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that …

CLASS ACTION DEADLINE: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines to File Lead Plaintiff Motions Related to the Following Companies: MYGN, OSTK, MTCH | 11/22/2019

… September 2, 2019 and August 13, 2019 Deadline: November 26, 2019 According to the complaint, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the FDA had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii …

DEADLINE ALERT - Myriad Genetics, Inc. (MYGN) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: November 26, 2019 | Globe Newswire | 11/22/2019

… recover damages against Defendants for alleged violations of the federal securities laws. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of …

6-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | 11/21/2019

510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint, Defendants misled investors about Myriad Genetics’ GeneSight ®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight ® product, while concealing that GeneSight ® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that …

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MYGN, CC and RUHN | 11/21/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl-and thereby, Foresight-caused …

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADTN, MTCH, MYGN and UA | Globe Newswire | 11/21/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

MYGN ALERT: Zhang Investor Law Reminds Investors of NOVEMBER 26 Deadline in Securities Class Action Lawsuit Against Myriad Genetics, Inc. – MYGN | Globe Newswire | 11/21/2019

… the class action. 如果您想加入这个集体诉讼案,请在这里提交您的信息。 http://zhanginvestorlaw.com/join-action-form/?slug=myriad-genetics-inc&id=2034 . According to the case, defendants made false and/or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of …

CLASS ACTION UPDATE for SNDL, MYGN, DOMO and ET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders | Globe Newswire | 11/21/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN | Globe Newswire | 11/20/2019

… psychotropic drug selection for depressed patients; and Foresight, a prenatal test in the expanded carrier screening market for future parents to assess their risk of passing on a recessive genetic condition to their offspring. GeneSight is offered as both a psychotropic 1 test (“GeneSight Psychotropic”) and MTHFR (an enzyme required to convert folic acid and dietary folate into its active form, which is called l-methylfolate) test. On September 1 …

Diagnostic Tests

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

… company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Markets Insider | Business Insider | 12/4/2019

… company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

Molecular Diagnostics

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

… LAKE CITY, Dec. 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Markets Insider | Business Insider | 12/4/2019

… LAKE CITY, Dec. 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

Precision Medicine

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

… 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen was published online … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Markets Insider | Business Insider | 12/4/2019

… 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen was published online … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

Food and Drug Administration

MYRIAD TUESDAY DEADLINE: ROSEN, A GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of November 26th Deadline in Securities Class Action | PR Newswire | 11/26/2019

GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (3) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (4) Myriad’s acquisition of Counsyl – and thereby, Foresight – caused the Company to incur …

Medicare

Treading with Caution | 11/22/2019

… their medication plan are warranted. Supporting best practices Among test developers supporting AMP’s “best practices” statement is Myriad Genetics. Its GeneSight Psychotropic Test is a laboratory-developed pharmacogenomic test designed to measure and analyze clinically … the FDA.” In addition to UHC, GeneSight is covered by Medicare, CareFirst, and Kroger Health. “We have ongoing conversations with other health plans,” Rogers said. “Payers and providers have consistently noted that they are most …

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of VRAY, MYGN and ZEN | 11/11/2019

… or failed to disclose that: (a) demand for ViewRay systems had declined due in part to changes being made to Medicare reimbursement approaches first announced in November 2019 that could make purchases of new ViewRay … statements and/or failed to disclose that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration …

Mental Health

Treading with Caution | 11/22/2019

… Genecept Assay until it was re-branded and re-launched in August). The test examines 24 key genes associated with mental health—information that, along with medical history, can help clinicians determine whether a drug … developers supporting AMP’s “best practices” statement is Myriad Genetics. Its GeneSight Psychotropic Test is a laboratory-developed pharmacogenomic test designed to measure and analyze clinically important genomic variants in treating psychiatric disorders. “As a laboratory …

The Speaking Length | 11/19/2019

… one night, I was carried out of a bar. A few years ago, I gave a public talk about my mental health. Its title, “Almost Aloud,” was a line clipped from the short story “Good … I started Lexapro. It did nothing. Six weeks later my GeneSight results came in. It sorted drugs into three categories: 1. Use As Directed; 2. Moderate Gene-Drug Interaction; and 3. Significant Gene-Drug Interaction …

Pharmacogenomic Testing

Dr. Mark H. Pollack named Chief Medical Officer for Myriad NeuroscienceHighly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice | BioSpace | 10/21/2019

Dr. Mark H. Pollack named Chief Medical Officer for Myriad NeuroscienceHighly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice Published: Oct 21, 2019 SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Mark H. Pollack, M.D., chief medical officer of Myriad Neuroscience effective Jan. 15 …

Kroger Health and Myriad Genetics Launch Pilot Program to Improve the Treatment of Depression | PR Newswire | 7/10/2019

CINCINNATI , July 10, Kroger Health, the healthcare arm of The Kroger Co. providing health, wellness, and nutrition solutions to more than 14 million people nationwide, announced its partnership with Myriad Genetics to pilot Myriad Genetics’ GeneSight® pharmacogenomic test with Kroger Prescription Plan members. Nearly 500 Kroger pharmacies across five states will participate in the GeneSight pilot. GeneSight is the market-leading genetic test to help clinicians personalize treatment plans for …

EndoPredict

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

… EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to more women receiving a correct answer the first time they are …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Markets Insider | Business Insider | 12/4/2019

… EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to more women receiving a correct answer the first time they are …

Henry Schein

CLASS ACTION UPDATE for CVET, MYGN, ZEN and PLT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders | The Wapakoneta Daily News | 11/25/2019

… capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein’s Animal Health Business and VFC, including the timing and nature of those costs … period and/or failed to disclose that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration …

CLASS ACTION UPDATE for CVET, MYGN, ZEN and PLT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders | Benzinga | 11/25/2019

… capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein’s Animal Health Business and VFC, including the timing and nature of those costs … period and/or failed to disclose that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration …

Assurex Health

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | PR Newswire | 11/23/2019

… Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with two new products—ForeSight and Prelude—in the expanded carrier screening and non-invasive prenatal testing markets, respectively. The company estimated that these markets would grow to approximately three million tests performed in the U.S. and $1.5 billion …

Myriad Genetics

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tencent, Myriad Genetics, Overstock.com, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 11/14/2019

… reminds investors that class action lawsuits have been commenced on behalf of stockholders of Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN), Overstock.com, Inc. (NASDAQ: OSTK), and Waitr Holdings, Inc. (NASDAQ: WTRH … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

electroCore

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sundial, electroCore, Tencent, and Myriad Genetics and Encourages Investors to Contact the Firm | Globe Newswire | 11/7/2019

… firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sundial Growers, Inc. (NASDAQ: SNDL), electroCore, Inc. (NASDAQ: ECOR ), Tencent Music Entertainment Group (NYSE: TME), and Myriad Genetics, Inc. (NASDAQ … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against electroCore, Tencent Music, Myriad Genetics, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 10/30/2019

… a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of electroCore, Inc. (NASDAQ: ECOR ), Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

UnitedHealth

Myriad Genetics Limps Into Fiscal 2020 | Yahoo News | 8/15/2019

… Myriad also disclosed an update in its communications with the U.S. Food and Drug Administration regarding requested changes to the GeneSight Psychotropic test, which helps patients determine the most effective treatment for depression and is … which matches individuals to depression treatments, would be covered by UnitedHealthcare . The news sent shares soaring nearly 60% as investors clamored over the idea that more major insurers would follow suit and help unlock the …

Myriad Genetics faces risk after FDA asks for GeneSight test changes - Business Insider | 8/14/2019

The pioneering genetic-testing company Myriad Genetics sells a test called GeneSight that claims to analyze a patient’s DNA and point them to the best depression drug for them. Scientists and doctors have raised concerns … Tycho Peterson and his team said. This news comes after UnitedHealth Group, the nation’s largest health insurer, said it would start covering GeneSight and other such tests for certain patients, starting in October. Myriad Genetics …

Massachusetts General Hospital

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

Highly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice October 21, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad … of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. He is past president of the Anxiety and Depression Association of America and served as chairman of its Scientific Advisory Board. Dr …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience Nasdaq:MYGN | Globe Newswire | 10/21/2019

… chief medical officer of Myriad Neuroscience effective Jan. 15, 2020. In this role, Dr. Pollack will lead efforts to make GeneSight standard-of-care in clinical practice. Dr. Pollack will report to Mark Verratti, president … of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. He is past president of the Anxiety and Depression Association of America and served as chairman of its Scientific Advisory Board. Dr …

Harvard Medical School

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

Highly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice October 21, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad … to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. He is past president of the Anxiety …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience Nasdaq:MYGN | Globe Newswire | 10/21/2019

… chief medical officer of Myriad Neuroscience effective Jan. 15, 2020. In this role, Dr. Pollack will lead efforts to make GeneSight standard-of-care in clinical practice. Dr. Pollack will report to Mark Verratti, president … to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. He is past president of the Anxiety …

Rush University Medical Center

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

Highly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice October 21, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad … as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience Nasdaq:MYGN | Globe Newswire | 10/21/2019

… chief medical officer of Myriad Neuroscience effective Jan. 15, 2020. In this role, Dr. Pollack will lead efforts to make GeneSight standard-of-care in clinical practice. Dr. Pollack will report to Mark Verratti, president … as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center …

Rush University Medical Center, Chicago IL

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

Highly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice October 21, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad … as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience Nasdaq:MYGN | Globe Newswire | 10/21/2019

… chief medical officer of Myriad Neuroscience effective Jan. 15, 2020. In this role, Dr. Pollack will lead efforts to make GeneSight standard-of-care in clinical practice. Dr. Pollack will report to Mark Verratti, president … as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center …

UnitedHealthcare

Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results | BioSpace | 11/5/2019

GeneSight ® Announced coverage decision from UnitedHealthcare, the largest commercial payer in the United States, covering GeneSight for patients that have a diagnosis of major depressive disorder or anxiety and have failed at least one prior medication. Signed master service agreement with a large pharmacy benefit manager in the United States to offer GeneSight to its commercial payer and self-funded employer customers. A Fortune 50 company has already opted into …

Genetic Tests For Psychiatric Drugs Now Covered By Some Insurers : Shots - Health News : NPR | 10/17/2019

… Meehan, an industry analyst for Barclays. Myriad reported that it sold $113 million worth of the tests. In addition to UnitedHealthcare’s coverage, Myriad Genetics’ test is covered by Medicare, a regional Blue Cross Blue Shield … says of all the tests claiming to improve depression treatment, GeneSight’s has the most proof. That isn’t saying much, though. “I wouldn’t say there’s no evidence that it works,” he says. “It’s just the evidence …

Bragar Eagel

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | PR Newswire | 11/23/2019

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm News provided by Nov 23, 2019, 12:00 ET … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

Robert S. Willoughby

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN | Globe Newswire | 11/20/2019

Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Myriad is a molecular diagnostic company that develops and markets predictive, personalized, and prognostic medicine tests worldwide. Myriad offers, among other products, GeneSight, a DNA …

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN | Benzinga | 11/20/2019

Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Myriad is a molecular diagnostic company that develops and markets predictive, personalized, and prognostic medicine tests worldwide. Myriad offers, among other products, GeneSight, a DNA …

Phillip Kim

ROSEN, A LEADING GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of Important Deadline in Securities Class Action – MYGN | Business Wire | 11/10/2019

… the federal securities laws. To join the Myriad class action, go to http://www.rosenlegal.com/cases-register-1685.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for … or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration …

Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Globe Newswire | 11/7/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … questioned the claims of marketed genetics tests, such as Myriad’s GeneSight. Myriad also disclosed that “the FDA requested changes to the GeneSight test offering” after Myriad had provided the FDA with clinical evidence and other …

Howard G. Smith

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Globe Newswire | 10/28/2019

October 28, 2019 11:00 ET Source: Law Offices of Howard G. Smith BENSALEM, Pa., Oct. 28, 2019 (GLOBE NEWSWIRE) – Law Offices of Howard G. Smith reminds investors of the upcoming November 26, 2019 deadline to … questioned the claims of marketed genetics tests, such as Myriad’s GeneSight. Myriad also disclosed that “the FDA requested changes to the GeneSight test offering” after Myriad had provided the FDA with clinical evidence and other …

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Benzinga | 10/28/2019

BENSALEM, Pa., Law Offices of Howard G. Smith reminds investors of the upcoming November 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Myriad … questioned the claims of marketed genetics tests, such as Myriad’s GeneSight. Myriad also disclosed that “the FDA requested changes to the GeneSight test offering” after Myriad had provided the FDA with clinical evidence and other …

Reed Kathrein

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, REMINDS MYGN INVESTORS OF CLASS ACTION: Myriad Genetics (MYGN) Investors Who Suffered Significant Losses are Encouraged to Contact the Firm | Globe Newswire | 10/24/2019

510) 725-3000 MYGN Securities Class Action: According to the Complaint , Defendants misled investors about Myriad Genetics’ GeneSight®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted … whether Myriad misrepresented GeneSight®’s benefits,” said Hagens Berman partner Reed Kathrein. Whistleblowers: Persons with non-public information regarding Myriad should consider their options to help in the investigation or take advantage of the SEC …

Colleen Lindholz

Here’s what Kroger stands to gain from its new partnership with Myriad Genetics (KR) | Business Insider | 7/16/2019

… chain Kroger announced it’s teaming up with Salt Lake City-based genetic testing company Myriad Genetics to bring the company’s GeneSight test to select members of Kroger’s employee health plan, per MedCity News. Business Insider … pension costs.” And in a press release , Kroger Health President Colleen Lindholz called depression — which affects over 17 million people in the US — the No. 1 cause of disability and lost productivity in the country …

Kroger Health and Myriad Genetics Launch Pilot Program to Improve the Treatment of Depression | PR Newswire | 7/10/2019

GeneSight® pharmacogenomic test with Kroger Prescription Plan members. Nearly 500 Kroger pharmacies across five states will participate in the GeneSight pilot. GeneSight is the market-leading genetic test to help clinicians personalize treatment plans for their patients with depression. “Depression is a leading cause of disability and lost productivity in the United States , and only 40 percent of people reach remission after their first antidepressant medication,” said Colleen Lindholz , President …